G01N33/686

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Anti-human IgG1 antibody

Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.

GENERATION OF HUMAN ALLERGEN- AND HELMINTH-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
20210382064 · 2021-12-09 · ·

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

RABBIT ANTIBODIES TO HUMAN IMMUNOGLOBULINS G
20210380719 · 2021-12-09 · ·

This disclosure anti-human IgG antibodies and antigen-binding portions thereof derived from rabbits and methods of using these antibodies and portions.

METHOD FOR DETECTING OR MONITORING THE DEVELOPMENT OF A CHRONIC PROLIFERATIVE DISEASE BY IMMUNOASSAY
20220196669 · 2022-06-23 ·

The invention relates to an ex vivo method for detecting or monitoring the progression of a chronic proliferative disease, in a sample of human or animal serum or plasma, by immunoassay for the presence of antibodies in the sample, including at least one or several antibodies directed against benzo(a)pyrene.

The invention also relates to a kit for implementing such a method.

METHOD FOR DETECTING OR MONITORING THE DEVELOPMENT OF A CHRONIC DEGENERATIVE DISEASE BY IMMUNOASSAY
20220196684 · 2022-06-23 ·

The invention relates to an ex vivo method for detecting or monitoring the progression of a chronic degenerative disease, in a sample of human or animal biological fluid, by immunoassay for the presence of antibodies in the sample, including at least: one or more antibodies directed against at least one endobacterium, and one or more antibodies directed against a tryptophan oxidation product.

The invention also relates to a kit for implementing such a method.

METHOD AND COMPOSITION FOR DETECTION OF PROTEOLYTIC PRODUCTS AND DIAGNOSIS OF MALIGNANT NEOPLASTIC DISEASE

Tumor invasion and metastasis is accompanied by significant activations of specific proteolysis enzymes. Tumor area is known to have increased infiltration of immunoglobulins G (“IgG”), so IgG may undergo proteolysis in this area. Serine proteases usually cleave peptide bonds between positively charged amino acids lysine and arginine. Since the intact PLG molecules as well as its fragments have lysine binding sites, they can bind to damaged IgG or fragments thereof with free C-terminal lysine that can appear in a circulation after proteolysis in the malignant tumor area. In the present invention we demonstrated the increased binding of damaged IgG or fragments thereof with free C-terminal lysine to fragments of PLG in samples from patients with breast cancer, ovarian cancer, lung cancer, colorectal cancer, prostate cancer vs. samples from healthy donors, and thus we proposed a novel diagnostic method.

Methods and reagents for determining immunoglobulin gamma (IgG) antibody isotype concentration from biological samples

Disclosed herein are methods and reagents for determining immunoglobulin gamma (IgG) antibody isotype concentration from biological samples, and for analyzing a plurality of cell samples for IgG antibody production.

Antibody selection method

Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.

Composition for diagnosing allergies to mites, method of diagnosing allergies to mites, and composition for preventing or treating allergies to mites

Mite proteins according to an aspect may be used in diagnosing allergic diseases. Results of diagnosing allergic diseases by using the proteins have high reliability and validity. Further, the proteins may be used in a composition for preventing or treating allergic diseases.